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One of the rapidly developing directions of 
biomedical research and nanotechnology 
is the design of new delivery systems, 
in particular, for the delivery of genetic 
information. Majority of the established 
immortalized cells lines broadly used by 
the scientific community allow efficient 
RNA and DNA transfer using lipid-, poly-
saccharide-, polymer-, or calcium precipita-
tion-based commercially available reagents. 
However, manipulation of gene expres-
sion in primary cells, including adult and 
embryonic stem cells and cancer stem cells 
representing attractive tools for regenera-
tive medicine, cancer therapy, and immune 
disease treatment, remains still an 
Efficient delivery of genetic material to primary cells remains challenging. Here, 
efficient transfer of genetic material is presented using synthetic biodegradable 
nanocarriers, resembling extracellular vesicles in their biomechanical 
properties. This is based on two main technological achievements: generation 
of soft biodegradable polyelectrolyte capsules in nanosize and efficient 
application of the nanocapsules for co-transfer of different RNAs to tumor cell 
lines and primary cells, including hematopoietic progenitor cells and primary T 
cells. Near to 100% efficiency is reached using only 2.5 × 10−4 pmol of siRNA, 
and 1 × 10−3 nmol of mRNA per cell, which is several magnitude orders below 
the amounts reported for any of methods published so far. The data show 
that biodegradable nanocapsules represent a universal and highly efficient 
biomimetic platform for the transfer of genetic material with the utmost 
potential to revolutionize gene transfer technology in vitro and in vivo.
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unsolved challenge.[1,2] Either viral transduction or electropora-
tion-based methods were shown to be most successful regarding 
transfer efficiency.[3] However, these methods have unwanted 
side effects hampering translation of in vitro findings to in vivo 
models. More complexity is expected by translation of this tech-
nique to clinical practice, which requires additional features, as 
the regulated duration of substance release, cost-effectiveness, 
and biocompatibility.[4]
Being a natural communication system between the cells, 
extracellular vesicles (EV),[5] have great potential as an approach 
for specific delivery of genetic information.[6] The main advan-
tages of naturally produced EVs compared with other common 
carriers, e.g., lipid-based nanoparticles, is their high penetra-
tion ability, delivery efficiency, and biocompatibility.[7] However, 
because they possess low loading efficacy, especially for RNA 
molecules,[8] and because manipulation of naturally produced 
EVs as well as the production of biomimetic nanovesicles[9] is 
time- and cost-intensive, alternative carriers sharing the biome-
chanical properties of natural vesicles and the loading capacity 
of synthetic carriers can be an attractive alternative.
Polyelectrolyte microcapsules have been developed as a potent 
drug delivery system.[10] For some applications, porous micron 
and submicron-sized CaCO3 particles have been used as bio-
compatible templates with appropriate chemical and mechanical 
stability, and flexible structural parameters, allowing efficient 
incorporation of various payloads.[11–15] As a further develop-
ment, CaCO3 particles have been adopted as a template to 
produce polyelectrolyte capsules using the Layer-by-Layer (LbL) 
technique. Being based on electrostatic interactions of charged 
species positioned on adjacent layers, LbL has an unequaled 
degree of multifunctionality.[16,17] By application of biocompat-
ible and biodegradable chemicals, biodegradable polyelectrolyte 
microcapsules have been developed as an attractive carrier for tar-
geting intracellular molecules,[18–21] and have been successfully 
tested for transfer of drugs and RNA including the incorporation 
of CRISPR-Cas9 system.[21–25] However, these attractive applica-
tions were mainly tested on immortalized cancer cell lines as 
proof of concept studies. The manipulation of primary and stem 
cells was not possible by the use of the microcapsules because of 
their toxicity and low uptake efficiency.[26] Here, we have tested a 
hypothesis that nanosized carriers might hijack natural intracel-
lular traffic pathways and consequently, transfer with high-effi-
ciency genetic material to any cell type without toxic side-effects. 
Few works published before, supported this hypothesis, demon-
strating proof of concept experiments, e.g., production of PEG 
LbL-based nanocapsules with paclitaxel or camptothecin core,[27] 
exhibiting significantly improved activity of camptothecin.[28]
First, we develop a new protocol for the production of nano-
sized CaCO3 core crystals to enrich a decrease of the core 
size from commonly used 3–5 µm to 300–600 nm diameter 
(Figure 1A and Figure S1: Supporting Information). The uptake 
efficiency, toxicity, capsules degradation, and the efficiency 
of RNA delivery were then extensively characterized using 
the HT1080 fibrosarcoma cell line (Figure 1B and Figure S2: 
Supporting Information). In pursuing our main goal of devel-
oping a carrier system mimicking natural extracellular vesicles 
(EVs) containing functional RNA,[29–34] we compared intracel-
lular localization of EVs and nanocapsules after their uptake. 
For that, HT1080 cells were treated either with fluorescently 
labeled EVs or with fluorescently labeled nanocapsules. Con-
focal microscopy revealed their similar intracellular localization 
(Figure S2B, Supporting Information). Both were detectable 
in the perinuclear regions and endocytic compartments sup-
porting our rationale that nanosized capsules will be delivered 
to the same intracellular compartments as the vesicles, possibly 
employing their intracellular routes. One can speculate that in 
contrast to microcapsules internalized mostly by a cholesterol-, 
and caveolin-dependent pathway[20,21,35–37] and located in the 
cytoplasm,[38,39] nanocapsules, similar to nanoparticles, due 
to their smaller size, are internalized via clathrin-mediated 
endocytosis,[40] which is also one of the main pathways for the 
internalization of exosomes.[41] However, also other pathways 
cannot be excluded, like, e.g., direct entry into the cells, due to 
the positively charged polyarginine moieties binding to with 
the cell membrane through electrostatic interactions and inten-
sively used for the transfer of quantum dots into the cells.[42] 
The intracellular traffic routes of nanocapsules in different cell 
types are not examined yet and will be intensively addressed 
in future studies. Here we show proof of concept experiments 
demonstrating their great potential.
We addressed the kinetics of RNA release from the biode-
gradable nanocapsules. As shown in Figure 1B, 4 h after treat-
ment, the Rdn-ctrsiRNA-488 capsules were detected within the 
cells. RdnB (red color) was fully merged with the siRNA-488 
(green color), indicating that RNA was still entrapped within 
the intact capsules (Figure 1B, left panel). The fluorescence 
signal was increased after 24 h, suggesting that more capsules 
were internalized. Only a portion of RdnB signal was merged 
with the siRNA-488 signal, indicating capsule degradation and 
release of the siRNA-488 from the capsules (Figure 1B, middle 
panel). A decrease of the fluorescent signal was observed after 
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48 h of incubation, suggesting that the majority of capsules 
degraded. Only a few large red spots, which could represent 
agglomerated dye, were detected in the cytoplasm partly colo-
calized with actin filaments or residual RNA (Figure 1B, right 
panel). Quantitative analysis revealed that about 51% of the cap-
sules remained intact after 24 h, and about 19% of the capsules 
remained intact after 48 h (Figure 1C,D). This indicates that 
due to the intracellular proteolytic activity, the majority of the 
capsules were degraded between 24 and 48 h, allowing the con-
secutive release of RNA within the cells.
To test the efficiency of our approach, we employed a 
simple conventional method of knocking down GFP, stably 
Small 2020, 16, 1904880
Figure 1. Capsules characterization and determination of efficiency uptake. A) SEM image of a vaterite CaCO3 particle (left panel) and hollow poly-
meric capsules (middle panel). Scale bar insert 250 nm, scale image 5 µm; Nanoparticle tracking analysis showing size distribution of nanocapsules 
B) Analysis of degradation kinetic of polyelectrolyte nanocapsules. To examine the degradation of capsules within the cells, HT1080 cells were treated 
with capsules loaded with RdnB and ctrsiRNA-488. Then 4, 24, and 48 h after treatment, the cells were fixed, stained with phalloidin and DAPI and 
subjected to confocal microscopy (scale bar 30 µm). C) Quantitative analysis of capsule degradation using ImageJ (4 h (dark red), 24 h (red), and 48 h 
(light-red)). A dark red diagram indicates the intensity of the yellow signal, showing that majority of capsules is intact; red and light-red diagrams show 
the intensity of yellow color after 24 and 48 h respectively, showing a decrease of a number of the intact capsules. D) Diagram, showing a decrease of 
the intact capsules from 100% after 4 h to only 19% after 48 h.
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overexpressed at a high level in HT1080 cells (Figure S3, 
Supporting Information). The HT1080-GFP cells were treated 
with nanocapsules loaded with a control siRNA and GFP-
specific siRNA (GFPsiRNA). As a control, the cells were 
transfected with Lipofectamine 2000 using the same amount 
of siRNA, corresponding to 2.5 × 10−4 pmol siRNA per cell 
(Figure S3B, Supporting Information). No residual GFP signal 
could be detected in the cells treated for 48 h with the nano-
capsules containing GFPsiRNA, in contrast to the cells trans-
fected with GFPsiRNA using Lipofectamine 2000. Quantitative 
analysis based on calculation of the intensity of the green fluo-
rescence signal revealed 80% reduction of green fluorescence 
in the cells treated with nanocapsules filled with GFPsiRNA 
and only 21% reduction of GFP signal in the cells transfected 
with Lipofectamine 2000; no unspecific effects were observed 
by the application of capsules loaded with the control siRNA 
(Figure S3, Supporting Information). These results suggest 
that biodegradable nanocapsules possess utmost high transfer 
efficiency of RNA molecules with no toxic effect.
Interestingly, by application of biodegradable microcapsules 
1–3 µm diameter, to enrich a comparable knockdown efficiency 
of 80% in cell lines, 500 pmol/10 capsules/cell siRNA were 
required,[21] which is 2 × 106 fold more than we used in the 
current work applying 2.5 × 10−4 pmol siRNA/20 capsules/
cell. This comparison argues strongly for unique properties of 
nanocapsules as highly efficient nucleic acids carriers required 
several magnitude lower amount of material as microcapsules 
or any other method reported so far. It is crucial at two points, 
firstly, because of a smaller risk of potential unspecific off-target 
effects by the application of nanocapsules required less RNA 
for the efficient transfer; and secondly, because of consider-
ably lower costs which will be required for scaling-up of the 
technology and industrial production.
Next, we tested the stability of nanocapsules. Mesenchymal 
stem cells (MSCs) isolated from the bone marrow were treated 
with nanocapsules loaded with AllStars Cell Death Control 
siRNA (apoptsiRNA) containing highly potent validated siRNAs 
targeting ubiquitous cell survival genes. Additionally, nano-
capsules stored for one year at 4 °C were used. Cell phenotype 
was controlled after 24 and 48 h of incubation with capsules 
(Figure 2A). Quantitative analysis of cell viability revealed 71% 
reduction, which is comparable with the effect of Tween-20 used 
as a positive control for cell death (Figure 2B). Remarkably, cap-
sules stored for one year at 4 °C showed comparable efficiency, 
indicating their high stability (Figure 2A, Capsules (1y) panel). 
Comparable results were received by testing HT1080 cells, 
showing furthermore increased efficiency of core-free capsules 
as compared to the capsules, still containing a core (Figure S4, 
Supporting Information). It is likely that the application of 
a vaterite core with its subsequent removal provides several 
advantages as compared to other approaches. Thus, capsules 
containing hydroxyapatite nanoparticles as a core exhibited a 
significantly less efficient delivery.[43] Hydroxyapatite is consid-
erably less porous material compared to the vaterite. Possibly, 
the high porosity of vaterite allows for a more efficient coating 
of the core nanoparticles with polyarginine molecules. A higher 
number of positively-charged polyarginine molecules bind a 
higher number of negatively-charged RNA molecules; conse-
quently, mediating increased loading efficiency. Removal of the 
vaterite core further improved efficiency. We may speculate that 
calcium carbonate nanoparticles, one entering the cells, will 
modulate local intracellular pH,[11] leading to a delay of the deg-
radation of the layers, hampering the release of functional RNA 
molecules, which would lead to a decrease of delivery efficiency. 
It is also cannot be excluded that the core-free capsules only, 
due to the differences in weight, can easier penetrate the cells 
and escape the lysosomal pathway, allowing for more efficient 
delivery. Considerable experimental efforts will be required to 
prove this hypothesis and to learn more about the molecular 
mechanisms of capsules delivery and their intracellular traffic.
These data demonstrate the utmost high efficiency and 
stability of biodegradable core-free nanocapsules for the transfer 
of functional RNA molecules, which is highly relevant given 
their potential clinical application and GMP requirements.
We tested two further cell types, a breast cancer cell line 
MDA-MB-361 and primary breast cancer stem-like cells (BCSC), 
recently characterized elsewhere.[44] Both are highly resistant to 
any other transfer methods except for viral transduction and 
electroporation. First, a co-knockdown of two endogenously 
expressed genes coding for Tspan8 and E-Cadherin, respec-
tively, was performed using a co-transfer of corresponding 
siRNAs, which were loaded into the nanocapsules as a mixture. 
As control a scrambled siRNA was used (Figure 3C). Analysis 
of knockdown efficiency demonstrated results similar to the 
efficiency of GFP knockdown observed in the HT1080 cells. 
No Tspan8- or E-Cadherin specific fluorescent signal could 
be visualized. Quantification of siRNA effect using RT-PCR 
revealed up to 90% signal decrease (Figure S5, Supporting 
Information).
These data strongly support the universality of nanocapsules 
able to transfer genetic material with high efficiency to any type 
of cells, including stem cells, indicating their possible applica-
tion for in vivo manipulation of cancer and cancer stem cells, 
inaccessible until now with microcapsules or any of conven-
tional non-viral methods of gene transfer available so far. Also 
natural vesicles, such as exomes, exhibited considerably lower 
loading capacity and delivery efficiency of functional siRNA 
molecules to the cells.[45]
To get a step closer toward clinical application, we next tested 
transfer of nanocapsules into the primary T cells and CD34+ 
hematopoietic progenitor cells (HPC). Stem cells of hematopoi-
etic origin play key roles in a high number of physiological and 
pathological processes and their deregulation is linked to a variety 
of diseases, including HIV, cancer, immune-, autoimmune dis-
eases, and others. Consequently, a technology allowing gene 
transfer and genome editing of hematopoietic stem cells will 
open new avenues to conceptual changes in the treatment of 
previously incurable diseases.[46–48] Among all methods tested 
so far, viral transduction and electroporation were considered 
as most efficient and were successfully used.[49,50] However, the 
viral transfer and nucleofection may result in a considerable 
portion of cell death and undesired off-target effects.[51] There is 
a high need for the development of new technologies allowing 
specific gene delivery to malignant and nonmalignant hemat-
opoietic cells in therapeutic purposes. Due to their small size 
of 6.8 µm average diameter for T cells[52] and 8.2 µm average 
diameter for the HPCs,[53] they are inaccessible for micro-
capsule-based transfer.
Small 2020, 16, 1904880
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Figure 2. Efficient apoptosis induction in MSCs. A) Confocal images of MSCs treated either with capsules loaded with apoptsiRNA and ctrsiRNA, or 
transfected with Lipofectamine 2000 using the same amounts of siRNAs. All cells were cultured for 48 h, fixed and stained with phalloidin-Alexa488 
and DAPI prior microscopy. To control capsule stability, MSCs were treated with capsules stored for one year. B) The WST-1 assay was performed 
to quantify cell viability. Reduction of cell number was measured after application of fresh capsules and capsules stored for one-year. No significant 
reduction of cell viability could be detected in the control. C) Simultaneous loading and transfer of two independent siRNAs for knockdown Tspan8 and 
E-Cadherin –coding genes in MDA-MB-361 and breast cancer stem-like cells (BCSCs). Scrambled siRNA was used as a control (ctrsiRNA). Complete 
abolishment of Tspan8-and E-Cadherin specific fluorescent signals was observed after 48 h of treatment with nanocapsules.
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To adapt nanocapsules to the requirement of gene transfer 
into HPCs and T cells, we modified the protocol for capsule 
preparation to produce nanocapsules with an average diam-
eter of 160 nm, ensuring efficient uptake and low toxicity 
(Figure 3A). To mention is, that application of microcapsules 
or any capsules larger as reported on hematopoietic stem cells 
or T cells caused high toxicity. Addressing capsules transfer, we 
used Rhodamine-labeling as described above.
The analysis of uptake efficiency performed 48 h post-
treatment. For T cells, 10 capsules/cells and for CD34 cells, 
5 capsules/cells were considered as an optimal concentration 
(Figure 3B). Next, we addressed the applicability of 
nanocapsules for mRNA transfer. First, the transfer of GFP 
mRNA using 1 × 10−3 nmol mRNA per cell was performed and 
controlled on a single cell level (Figure 3C). Interestingly, in 
contrast to microcapsules, where the loss of RNA during encap-
sulation was reported, we did not observe it by the production 
of nanocapsules.[54]
A pilot proof of concept experiment aiming to test the func-
tionality of the transferred mRNA was performed on primary 
T cells. The nanocapsules were loaded with Cas9 mRNA and 
a guide RNA (gRNA) targeting the “HEK site 4” and used for 
the treatment of primary T cells. As a positive control, activated 
T cells were nucleofected with the same RNA using the 4D 
nucleofector. Cleaved fragments, indicating nuclease activity, 
were detected in the sample treated with capsules (cap) con-
taining the CRISPR/Cas9 RNAs and in the nucleofected control 
(nucl), but not in the untreated samples (UT), thus proving 
evidence for efficient capsule-mediated RNA delivery into 
primary T cells, and supporting their universality (Figure S6, 
Supporting Information).
Summarizing, our data show that nanocapsules resembling 
in their size and charge natural extracellular vesicles can 
universally be applied for transfer of functional RNA molecules 
to any type of cells with yet unmet efficiency, representing here-
with a new unique concept of biomimetic nanotransfer for a 
broad range of applications in vitro and in vivo.
Experimental Section
Materials: Anhydrous sodium carbonate, sodium chloride, ethylene 
glycol, calcium chloride, dextran sulfate sodium salt (DS, MW > 70 000), 
poly-l-arginine hydrochloride (PARG, MW > 70 000), Rhodamine B 
isothiocyanate (MW 536.08), phosphate buffered saline (PBS, 0.01 m), 
calcium chloride dihydrate, ethylenediaminetetraacetic acid disodium 
salt (EDTA), dimethyl sulfoxide (DMSO), were all obtained from Sigma-
Aldrich. RPMI-1640 medium, fetal bovine serum (FBS), was purchased 
from Thermo-Fischer Scientific. Control siRNA labeled with Alexa 488 
(ctrsiRNA-488) and AllStar Death Control siRNA (apoptsiRNA) were 
purchased from Qiagen.
Nanocapsules Preparations for the Transfer of RNA in Tumor Cells: 
The final size of the vaterite particles depends strongly on the 
concentration of the salts used.[55,56] The experience showed that also 
reaction time and the rotation during mixing are critical. Therefore, a 
new protocol was developed, allowing to decrease substantially the 
size of vaterite particles. 1 mL of 0.33 m Na2CO3 and 1 mL of 0.33 m 
CaCl2 were dissolved in 10 mL ethylene glycol (EG) and rapidly mixed 
under magnetic stirring for 3 h. After 3 h of stirring, the particles were 
sediment by centrifugation, resuspended in 1 mL of ddH2O and stored 
at 4 °C until further use. The size of CaCO3 particles obtained was in the 
range of 300–600 nm
Nanocapsules Preparations for the Transfer of RNA in Primary Cells: 
For RNA transfer into the human CD34 hematopoietic stem cells and 
primary T cells smaller capsules were produced. For that, a new protocol 
was developed for the preparation of CaCO3 nanoparticles. Firstly, 
gelatin (3 g) was dissolved in ddH2O (50 mL) and heated to 90 °C. 
After that, the gelatin solution was rapidly mixed upon magnetic stirring 
with 99% Glycerol (50 mL). Taking into account that the size of valerate 
crystals is strictly dependent on salt concentration,[56] 0.1 m Na2CO3 
(10 mL) and 0.1 m CaCl2 (10 mL) were mixed as stirred for 24 h. The 
fabricated particles were sediment by ultracentrifugation at 40 000 × g 
and washed with hot water (70 °C). After that, nanoparticles of CaCO3 
were covered by polymers (PARG/DS)2.
RNA and Dye Encapsulation: Encapsulation of a dye was developed 
using the layer-by-layer (LbL) technique. The LbL technique is based 
on the sequential adsorption of oppositely charged molecules, such 
as polyelectrolytes, onto a charged sacrificial template. For the layers, 
biocompatible polyelectrolytes Dextran Sulfate (DS) 1 mg mL−1 (2 mL) 
and poly-l-arginine hydrochloride (PARG) 1 mg mL−1 (1 mL) were 
applied. For the preparation of labeled capsules, rhodamine isocyanate 
(concentration 1 mg mL−1) was added as a first layer to CaCO3 particles 
diluted in 2 mL of ddH20 which was conjugated with polymer PARG. 
Then 2 layers of DS and PARG were coated consequently. For the 
encapsulation of RNA, a new method was developed. First, 50 µL of 
the 20 pmol siRNA solution was diluted in 1 mL RNase-free, DNase-
free ddH20. If 2 different siRNAs were applied, a 1:1 mixture was 
prepared. If mRNA was encapsulated, 1–5 µg mRNA in the presence 
of RNase inhibitor was used. The RNA layers were coated on the 
PARG layer and covered again with a PARG layer. It is important that 
the last layer has a positive charge. Next, the core was removed with 
ethylenediaminetetraacetic acid (EDTA); capsules were resuspended in 
1 mL ddH2O and final concentration 8 × 108 mL−1.
siRNA and mRNA Transfer by Capsules and Transfection: One day 
before transfection or treatment with capsules, tumor cells and MCSs 
were seeded in 4-well or 8-well chamber slides (Ibidi) using 2 × 104 cells 
in 300 µL of cell culture medium per well and grown overnight to the 
expected cell density of 60–70%. Capsules were added at concentration of 
20 capsules per cell and incubated for the desired duration. For transfection 
Lipofectamine 2000 was used; transfection was performed according to the 
recommendation of the supplier. Cells were transfected with an amount 
of siRNA, corresponding to the amount of siRNA loaded in the capsules. 
Thus, 1,6 × 106 capsules and 20 pmol siRNA were used for 8 × 104 cells for 
treatment or transfection respectively.
Scanning Electron Microscopy (SEM): Capsule morphologies were 
examined using scanning electron microscopy (SEM MIRA II LMU 
(TESCAN). Capsule suspension was dropped to the silicon surface, 
dried, coated with gold. SEM observation was carried out using an 
accelerating voltage of 10 kV. To visualize cells uptake and evaluate 
capsules, a confocal laser microscopy system was used.
Transmission Electron Microscopy (TEM): TEM was used to control 
the quality of EV preparations and their integrity. 10 µL of the vesicle 
preparation was loaded on a 300-mesh copper grid and fixed with 1% 
glutaraldehyde. Next, they were washed with double distilled water and 
negatively stained with 10 µL drop of 1% uranyl acetate and washed. 
Images were taken by the electron microscope (LEO 906 E, Zeiss, 
Oberkochen, Germany) using SIS software (Olympus, Hamburg, 
Germany).
Cell Lines and Primary Cells: Fibrosarcoma cell line HT1080 was 
purchased from the ATCC Cell culture collection and maintained in 
RPMI + 10% FBS at 37 °C and 5% CO2. MSCs were kindly provided by 
Bernd Giebel (Essen University Clinic, Essen Germany), BMSCs were 
kindly provided by Jochen Mauer (University Clinic Aachen, Aachen, 
Germany). Peripheral blood mononuclear cells (PBMCs) were isolated 
using phase separation and then frozen in liquid nitrogen until used. 
PBMCs were thawed and recovered for 24 h in RPMI complete medium 
supplemented with 10% fetal calf serum, penicillin (100 U mL−1), 
streptomycin (100 mg L−1) and HEPES (10 × 10−3 m). Then, T cells were 
activated using anti-CD2/CD3/CD2 antibodies (ImmunoCult, Stem Cell 
technology) and cultured with RPMI complete medium supplemented 
Small 2020, 16, 1904880
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Figure 3. Nanocapsules developed for the transfer of genetic material to primary T cells and hematopoietic stem cells. A) Scanning electron microscopy 
of the CaCO3 core (left panel), and ready-to-use capsules (middle panel). Scale bar 100 nm. Nanoparticle tracking analysis shows the size distribution 
between 50 and 280 nm with a peak of 160 nm (right panel). B) Flow cytometry analysis of T cells (upper panels) and CD34+ (bottom panels) cells 
treated with Rhodamine-labeled nanocapsules showed that application of 5 nanocapsules/cells is sufficient for an efficient transfer of capsules into 
CD34+ cells, and 10 nanocapsules/cell is sufficient for an efficient transfer of capsules into T cells . Application of higher nanocapsules number led 
to the reduction of cell viability (left panel). C) Confocal microscopy of T cells and CD34+ cells revealed efficient transfer of GFP mRNA. Images were 
taken 72 h post-treatment with capsules. Cells were stained with DAPI to visualized cell nuclei. Green fluorescence show cells expressing GFP after 
uptake of nanocapsules. Scale bar left panel 30 µm, right panel 9 µm.
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with 100 U mL−1 IL-2, 25 U mL−1 IL-7, and 50 U mL−1 IL-15 for 3 days 
before transfection. Cord blood CD34+ cells were purchased from 
Lonza. After thawing, cells were cultivated in GMP SCGM media 
(Cellgenix) supplemented with 60 ng mL−1 SCF, 60 ng mL−1 Flt3L, 
20 ng mL−1 TPO, 20 ng mL−1 IL3 (all from Immunotools), penicillin 
(100 U mL−1), streptomycin (100 mg L−1). At day 3, 1 × 106 activated 
T cells or 7.5 × 104 CD34+ cells were transfected with nanocapsules 
loaded with Rhodamine, in order to define the concentration of capsules 
allowing maximal uptake by minimal toxicity. All human experiments 
were performed in accordance with the Declaration of Helsinki. All 
patients involved provided written informed consent. The experimental 
protocols were approved by the institutional review board vote 307/13 
independent Ethics Committee of the University of Freiburg.
Viability Assay: To measure cytotoxicity and viability, WST-1 assay 
was performed according to the manufacturers’ recommendations. 
Briefly, cells were seeded in a 96-well plate and incubated overnight. 
After administration of capsules loaded with corresponding siRNAs or 
treated with Tween-20 used as a positive control for cell death, cells 
were cultured for 24, 48, or 72 h, respectively as required. WST1 reagent 
was added to each well and maintained for 4 h. The absorbance at 
450 nm was monitored using TECAN Elisa Reader and the reference 
wavelength was set at 630 nm. The relative cell viability percentage in 
each group was calculated by comparison to that of the control group.
Immunofluorescence: Two days before the experiment, 1.5 × 104 cells 
per well were seeded in the ibidi 8-well µ-slide chamber. On the day of 
staining, cells were fixed with 4% paraformaldehyde for 5 min at 37 °C, 
washed and permeabilized with 0.1% Triton-X 100. For staining, 
cytoskeleton phalloidin conjugated with either Alexa488 or Alexa594 
fluorophores was applied for 1 h and washed. Next, the nuclei were 
stained with DAPI for 20 min at room temperature, washed and incubated 
with Prolong Diamond anti-fade mountant, allowed to heal overnight at 
room temperature. Images were taken using a Leica confocal microscope 
(Leica TCS SP2 AOBS) equipped with an HCX PL APO 63× NA 1.4 oil 
immersion objective. Images for the different fluorophores were scanned 
sequentially. Further image processing was carried out using ImageJ.
Image Analysis: For quantitative evaluation of green signal intensity, 
ImageJ was used. The experiment was done in biological triplicates. For 
statistical analysis, five images of each delivery method were taken. For 
each image, the intensity distribution graph of the green signal over the 
area was plotted. Area statistics were calculated for the complete image 
and the average intensity value was calculated.
Flow Cytometry: To test the viability of T cells and CD34+ cells and 
the efficiency of capsule transfer, FACS analysis was performed using BD 
Accuri (BD Biosciences, NY, USA). Percentages of dead and apoptotic 
cells were measured by staining with 7-AAD (PanReac Applichem) stains 
following the manufacturers’ instructions. Cells treated with capsules for 
48–72 h were washed with 1 mL PBS and recovered by centrifugation 
at 300 × g for 5 min. Cell pellets were resuspended in 500 µL cold PBS, 
divided into two flow cytometry tubes for stained and unstained readout, 
and a minimum of 104 cellular events was recorded. Data analysis was 
performed with BD Accuri C6 Software (BD Biosciences, NY, USA), 
GraphPad Prism was used for statistics.
EV Isolation: For isolation of small EVs, cells were maintained under 
starvation conditions for 36 h. The harvested medium was centrifuged 
for 15 min at 2000 × g, followed by 45 min at 5000 × g and 30 min at 
12 000 × g. The supernatant was filtered with a 0.2 µm membrane and 
concentrated in a concentration chamber to achieve a volume of 30 to 
50 mL. This concentrated supernatant was centrifuged at 120 000 × g 
for 1.5 h. The resulting supernatant was discarded and the exosome 
pellet washed with 11.5 mL sodium chloride, followed by a second 
centrifugation step at 120 000 × g for 2 h. The supernatant was discarded 
and the exosome pellet resuspended with sodium chloride with a final 
volume of 200 µL per cell line.
Staining of Vesicles with PKH26: To produce fluorescent vesicles, 
HT1080 parental cells were stained with the PKH26 dye according to 
the recommendations of the supplier. Afterward, cells were washed and 
maintained for 36 h in the serum-free medium upon starvation. Conditions 
medium was used to isolate EVs according to the general protocol.
Nanoparticle Tracking Analysis: Exosome and Capsule concentration 
and size distribution were analyzed by nanoparticle tracking analysis 
(NTA) using the ZetaView system PMX110 (Particle Metrix, Meerbusch, 
Germany) according to the manufacturer’s instructions. Briefly, samples 
were diluted in filter-sterilized HEPES buffers; using ration 1:500 for 
exosomes and 1:100 for capsules. Images were recorded at 11 positions 
and five cycles with camera sensitivity 95%; shutter position 70; the 
temperature was monitored manually, ranged from 21 to 22 °C.
mRNA Loading: The same capsulation procedure was used for mRNA 
loading. mRNA was diluted in 100 µL of RNase free water. Capsules 
with structure (PARG/DS)2 in 100 µL from capsules stock solution was 
added to mRNA solution together with the RNase inhibitor. Solution 
capsules + mRNA was gently stirred for 30 min.
mRNA Transfer: One day before treatment with capsules, cells were 
seeded in 8-well chamber slides (Ibidi). 5 × 109 capsules were used 
for the treatment of 1 × 106 T cells; 2.5 × 109 capsules were used for 
the treatment of 7.5 × 104 CD34+ cells. After 48 h, cells were examined 
by flow cytometry and confocal microscopy. To test the applicability 
of nanocapsules to edit primary T cells, the cells were isolated as 
described above; the nanocapsules were loaded with Cas9 mRNA and 
a guide RNA (gRNA) targeting the “HEK site 4” genomic locus.[57] As 
a positive control, 1 × 106 activated T cells were nucleofected with 5 µg 
of mRNA encoding Cas9 and 75 pmol of gRNA targeting the “HEK 
site 4” locus using the 4D nucleofector according to the manufacturer 
recommendation (Lonza, P3 kit, EO-115 program). After transfer of 
capsules or nucleofection, respectively, T cells were recovered in 96-well 
plates for four days before assessing the nuclease cleavage activity 
at the target locus. The activity of the nuclease was controlled by 
measuring the extent of non-homologous end joining (NHEJ)-mediated 
mutagenic repair at the target site using the mismatch-sensitive T7 
endonuclease 1 (T7E1) assay. At day four post-transfection, cells were 
harvested and genomic DNA was extracted using direct lysis buffer 
mixed with proteinase K (20 mg mL−1). An amplicon encompassing 
the nuclease target site in the “HEK site 4” locus was generated by 
PCR using the primer pair (5′-AGGCAGAGAGGGGTTAAGGT-3′ and 
5′-GGGTCAGACGTCCAAAACCA-3′). Afterward, amplicons were purified 
using QIAquick PCR Purification Kit and subjected to digestion with 
T7E1 as previously described.[58] Cleaved fragments are an indication for 
the activity of the nuclease at the intended target site compared to the 
un-transfected (UT) sample were no cleaved fragments can be observed.
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